Monitor for the final prospectus and pricing announcement, as the offering price within the $6.00-$8.00 range will determine the actual capital raised and potential dilution. The success of the Nasdaq listing application is a critical next step, as the offering is contingent on it.
Executive Summary
Optimi Health Corp., a Canadian psychedelic pharmaceutical company, is conducting its U.S. IPO by registering 2.5 million common shares and associated warrants. The expected offering price is between $6.00 and $8.00 per share, with a total maximum aggregate offering price of $38.985 million. This filing is an amendment to update the filing fee table, indicating the IPO process is advancing toward effectiveness.
Key Financial Metrics
Key Facts
- Optimi Health Corp. is a Canadian company headquartered in British Columbia, operating in the psychedelic pharmaceutical space with GMP-compliant manufacturing of MDMA and psilocybin.
- This F-1/A amendment updates the filing fee table for the U.S. IPO, which is an exhibit-only filing with no changes to the prospectus.
- The company is offering 2,500,000 common shares with an expected price range of $6.00 to $8.00 per share, with additional warrants to be issued to the underwriter and underlying common shares.
- The total maximum aggregate offering price is $38,985,000, comprising $17.25 million from common shares, $1.035 million from shares underlying underwriter warrants, and $20.7 million from shares underlying common warrants.
- The company's shares are already listed on the Canadian Securities Exchange (OPTI), Frankfurt Stock Exchange (8BN), and OTCQX (OPTHF), and it seeks a Nasdaq Capital Market listing under OPTH, which is a condition for completing the offering.
Financial Impact
The IPO has a maximum aggregate offering price of $38.985 million, which will provide capital for scaling production, expanding into new markets like the U.S. and Israel, and funding general operations.
Risk Factors
- The company has a history of operating losses and lacks profitability, which is common for early-stage biotech firms but increases investment risk.
- Regulatory uncertainty exists, particularly in the U.S., where psychedelic substances like MDMA and psilocybin are classified as Schedule I drugs, creating hurdles for market approval and commercialization.
- The IPO's success depends on securing a Nasdaq listing, which is not guaranteed and could delay or prevent the offering from closing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001193125-26-166745 |
| Document: d43258dexfilingfees.htm | 0001193125-26-166745 |
| Document: 0001193125-26-166745-index-headers.html | 0001193125-26-166745 |
| Document: 0001193125-26-166745-index.html | 0001193125-26-166745 |
| Document: 0001193125-26-166745.txt | 0001193125-26-166745 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 26, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 19, 2026 22w ago | F-1/A | $0.2352 | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | F-1/A | $0.2644 $0.2352 | ▼ −11.04% | ▼ −15.07% | — |
Apr 21, 2026 26w ago | F-1/A | $0.2680 $0.2352 | ▼ −12.24% | ▼ −15.40% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers